We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT...
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...
Three Clinical Stage Programs Targeting PCSK9 and ANGPTL3 Expected in 2024 Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.15 | 2.39616613419 | 6.26 | 7 | 5.84 | 1092011 | 6.09558101 | CS |
4 | -2.12 | -24.8534583822 | 8.53 | 8.77 | 5.84 | 1109491 | 7.06821052 | CS |
12 | -5.63 | -46.7607973422 | 12.04 | 19.34 | 5.84 | 1306426 | 11.19920527 | CS |
26 | -7.69 | -54.5390070922 | 14.1 | 20.12 | 5.84 | 1465299 | 11.90416467 | CS |
52 | -9.05 | -58.5381630013 | 15.46 | 21.4199 | 5.84 | 1099995 | 12.92537565 | CS |
156 | -23.59 | -78.6333333333 | 30 | 78 | 5.84 | 864815 | 21.80781151 | CS |
260 | -23.59 | -78.6333333333 | 30 | 78 | 5.84 | 864815 | 21.80781151 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions